News
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

145,048 Results

Type

Article (3083)
Company Profile (29)
Press Release (141936)

Section

Business (47224)
Career Advice (87)
Deals (8424)
Drug Delivery (3)
Drug Development (29238)
Employer Resources (12)
FDA (2352)
Job Trends (3204)
News (85938)
Policy (5616)

Tag

Date

Today (23)
Last 7 days (122)
Last 30 days (517)
Last 365 days (11867)
2024 (6664)
2023 (12367)
2022 (14237)
2021 (16004)
2020 (13727)
2019 (8837)
2018 (6251)
2017 (8075)
2016 (6576)
2015 (8395)
2014 (6323)
2013 (4517)
2012 (4446)
2011 (4448)
2010 (4454)

Filters

Type

Article (3083)
Company Profile (29)
Press Release (141936)

Section

Business (47224)
Career Advice (87)
Deals (8424)
Drug Delivery (3)
Drug Development (29238)
Employer Resources (12)
FDA (2352)
Job Trends (3204)
News (85938)
Policy (5616)

Tag

Date

Today (23)
Last 7 days (122)
Last 30 days (517)
Last 365 days (11867)
2024 (6664)
2023 (12367)
2022 (14237)
2021 (16004)
2020 (13727)
2019 (8837)
2018 (6251)
2017 (8075)
2016 (6576)
2015 (8395)
2014 (6323)
2013 (4517)
2012 (4446)
2011 (4448)
2010 (4454)

145,048 Results for "keryx biopharmaceuticals".

Sort By

BioMidwest

Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders

Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.

June 13, 2024
·
5 min read
BioMidwest

Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.

June 20, 2024
·
5 min read
Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024

Kangpu Biopharmaceuticals today announced that a poster tour presentation highlighting the Phase 2a clinical data of KPG-818 in patients with Systemic Lupus Erythematosus (SLE) will be presented at the upcoming Annual European Congress of Rheumatology EULAR 2024, taking place in Vienna, Austria, June 12-15, 2024.

June 10, 2024
·
3 min read
Business

Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

Provectus Biopharmaceuticals, Inc. today announced additions to its executive leadership team, reflecting Provectus’s dedication to enhancing shareholder value.

April 16, 2024
·
6 min read
Deals

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas.

April 1, 2024
·
3 min read
Sanyou Biopharmaceuticals Launches Advanced Intelligent R&D Service Platform

Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the “Sanyou Intelligent Innovative Biologics R&D Service Platform,” representing a transformative advancement in biopharmaceutical research and development.

March 12, 2024
·
2 min read
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

HighField Biopharmaceuticals announced that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology annual meeting May 31-June 4, 2024, in Chicago, IL.

April 24, 2024
·
2 min read
Biotech Bay

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

XOMA Corporation, the biotech royalty aggregator, announced it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Review Voucher for $108 million to an undisclosed buyer.

June 12, 2024
·
4 min read
HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

HighField Biopharmaceuticals2 other diseases, said naturally occurred diabetic monkeys experienced weight loss and HbA1c level reduction during an assessment period of two months following a single injection with HFG1.

June 24, 2024
·
2 min read
Deals

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals

Sentynl Therapeutics, Inc. (Sentynl) and Eiger BioPharmaceuticals, Inc. (OTC: EIGRQ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced the closing of the sale of Eiger’s Zokinvy® (lonafarnib) program to Sentynl.

May 3, 2024
·
11 min read

1 of 14,505

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
Hotbeds
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin